ADELAIDE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous
Bionomics' Half-Year Report
February 23, 2022
ADELAIDE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), today announced its half-year report for the half-year ended 31 December 2021. The half-year ending 31 December 2021 represented a transformational period for Bionomics in which the Company made great
EASTWOOD, Australia, Jan. 14, 2022 /PRNewswire/ -- Bionomics Limited (Nasdaq: BNOX , ASX: BNO), a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet
ADELAIDE, Australia , Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited (ASX:BNO,NASDAQ: BNOX ) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually from January 10-13, 2022 .
EASTWOOD, Australia, Jan. 5, 2022 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutical company, today announced the issuance of 243,300 American Depositary Shares ( ADSs ), each representing 180 ordinary shares of Bionomics, pursuant to the exercise in
EASTWOOD, Australia, Jan. 3, 2022 /PRNewswire/ -- Bionomics Limited (ASX: BNO,NASDAQ: BNOX ) ( Bionomics or Company ), a clinical-stage biopharmaceutical company, is pleased to announce that it has initiated its Phase 2 clinical trial (the PREVAIL Study) to evaluate BNC210 for the acute